Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Sonja Witteveen, MD, The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses three-year outcomes from the Phase III NADINA (NCT04949113) trial comparing neoadjuvant ipilimumab plus nivolumab, followed by response-driven adjuvant…
Sonja Witteveen, MD, The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses how near-PCR patients had unexpectedly poor outcomes in the NADINA trial (NCT04949113) trial, highlighting that complete responders had…
Sonja Witteveen, MD, The Netherlands Cancer Institute, Amsterdam, Netherlands, describes a multicenter real-world analysis of neoadjuvant ipilimumab plus nivolumab in resectable stage III melanoma, comparing treatment-naïve patients with…
Steven Wijnen, The Netherlands Cancer Institute, Amsterdam, Netherlands, describes a NADINA (NCT04949113) trial analysis linking the CD16a-F158V variant, a germline change that strengthens Fc receptor binding, to poorer…
Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the long-term data from a Phase I study (NCT03005782) of fianlimab and cemiplimab, noting that…
Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses long-term survival follow-up from a Phase I study (NCT03005782) of fianlimab, an anti-LAG-3 antibody, plus…
Steven Wijnen, The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses the impact of Fc-gamma receptor affinity on patient outcomes in relation to immunotherapy in melanoma, noting that the effect…
Jason Chan, MD, University of California, San Francisco, CA, discusses dose expansion results from the Phase I (NCT03589339) study evaluating a single intratumoral injection of NBTXR3, a hafnium…
Jason Chan, MD, University of California, San Francisco, CA, comments on the potential of NBTXR3, a first-in-class radioenhancer, in combination with radiation therapy for the treatment of melanoma,…
Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, comments on the potential of a fianlimab and cemiplimab in melanoma treatment, highlighting its potential to…